Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Stocks - Pfizer, Raytheon Rise Premarket, McDonald's Falls

Published 2020-07-28, 08:10 a/m
© Reuters.

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Tuesday, July 28th. Please refresh for updates.

  • Pfizer (NYSE:PFE) stock rose 2.8% after the pharmaceutical company raised its guidance for the full year, after its revenue and profit fell by less than expected in the second quarter. Pfizer and Biontech (NASDAQ:BNTX), up 3.4%, had said late Monday that they have started a late-stage clinical trial for one of their Covid-19 vaccine candidates, involving 30,000 people around the world.

  • 3M (NYSE:MMM) stock fell 2.8% after the industrial giant reported a 12% drop in quarterly revenue, as results were "significantly impacted" by the Covid-19 pandemic.

  • Raytheon (NYSE:RTN) Technologies (NYSE:RTX) stock rose 3% after the company reported better than expected second-quarter numbers, helped by a "good performance" in its defense business.

  • McDonald’s (NYSE:MCD) stock fell 4.3% after the fast food giant disappointed with its second-quarter results, as a sharp drop in its overseas sales weighed on earnings.

  • Harley-Davidson (NYSE:HOG) stock fell 4.9% after it unexpectedly swung to a loss in the second quarter as coronavirus shutdowns hit motorcycle sales.

  • Tesla (NASDAQ:TSLA) stock fell 2.3%, handing back some of Monday’s 8.7% gain, after Bernstein downgraded the stock to ‘underperform’, saying “we find it difficult to justify Tesla's current valuation even under our most bullish/imaginative scenario.”

  • S&P Global (NYSE:SPGI) stock rose 0.4% after its revenue grew 14% in the second quarter, as the pandemic led to a surge of corporate bond issuance.

  • DR Horton (NYSE:DHI) stock rose 3.1% after the home construction company reported a 33% rise in fiscal third-quarter profit, despite uncertainty due to the pandemic.

  • Eastman Kodak (NYSE:KODK) soared 203% after the one-time photography leader announced it had received a $765 million government loan to help expedite domestic production of some drugs. 

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.